Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Congenital chloride diarrhea Indication Strategy Report 2026: SLC26A3, Trials and Deals
24 July 2026
2026 Congenital chloride diarrhea strategy: epidemiology, SLC26A3 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Small intestinal bacterial overgrowth Indication Strategy Report 2026: Methanogen reductase, Trials and Deals
24 July 2026
2026 Small intestinal bacterial overgrowth strategy: epidemiology, Methanogen reductase biology, clinical competition, recent deals, unmet need and market…
Latest Hotspot
8 min read
Perianal fistulizing Crohn disease Indication Strategy Report 2026: TNF, Trials and Deals
24 July 2026
2026 Perianal fistulizing Crohn disease strategy: epidemiology, TNF biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Ulcerative proctitis Indication Strategy Report 2026: JAK1, Trials and Deals
24 July 2026
2026 Ulcerative proctitis strategy: epidemiology, JAK1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Tropical sprue Indication Strategy Report 2026: Folate receptor, Trials and Deals
24 July 2026
2026 Tropical sprue strategy: epidemiology, Folate receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Whipple disease Indication Strategy Report 2026: Tropheryma whipplei, Trials and Deals
24 July 2026
2026 Whipple disease strategy: epidemiology, Tropheryma whipplei biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Autoimmune enteropathy Indication Strategy Report 2026: JAK1, Trials and Deals
24 July 2026
2026 Autoimmune enteropathy strategy: epidemiology, JAK1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Refractory celiac disease Indication Strategy Report 2026: IL-15, Trials and Deals
24 July 2026
2026 Refractory celiac disease strategy: epidemiology, IL-15 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Cutaneous sarcoidosis Indication Strategy Report 2026: TNF, Trials and Deals
24 July 2026
2026 Cutaneous sarcoidosis strategy: epidemiology, TNF biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Pityriasis rosea Indication Strategy Report 2026: HHV-6, Trials and Deals
24 July 2026
2026 Pityriasis rosea strategy: epidemiology, HHV-6 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Pityriasis lichenoides Indication Strategy Report 2026: TNF, Trials and Deals
24 July 2026
2026 Pityriasis lichenoides strategy: epidemiology, TNF biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Eosinophilic pustular folliculitis Indication Strategy Report 2026: PGD2 receptor, Trials and Deals
24 July 2026
2026 Eosinophilic pustular folliculitis strategy: epidemiology, PGD2 receptor biology, clinical competition, recent deals, unmet need and market attractiveness.